Drugs / NNC4005-0001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07214870 | Oct 2025 → May 2027 expected | fatty liver disease | Novo Nordisk A/S | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC4005-0001 | “Participants will receive a single dose of NNC4005-0001 injected subcutaneously.” NCT07214870 ↗ |
| Route | Subcutaneous | “via subcutaneous route” NCT07214870 ↗ |